News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ultragenyx Pharmaceuticals Announces Presentation of Three Abstracts at the 12th International Congress of Inborn Errors of Metabolism (ICIEM 2013)


8/28/2013 9:47:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NOVATO, Calif., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced three abstracts related to UX007, a substrate replacement therapy intended for the treatment of fatty acid oxidation disorder (FAOD), and UX003, an enzyme replacement therapy intended for the treatment of mucopolysaccharidosis type 7 (MPS 7, Sly syndrome). The abstracts will be presented at the 12th International Congress of Inborn Errors of Metabolism on September 3-6, 2013 in Barcelona, Spain.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES